INVESTOR DEADLINE TOMORROW: Robbins Geller Rudman & Dowd LLP Announces that Organon & Co. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – OGN

Core Viewpoint - A class action lawsuit has been filed against Organon & Co. for alleged violations of the Securities Exchange Act of 1934, focusing on misleading statements regarding the company's financial health and projections during the Class Period from November 3, 2022, to April 30, 2025 [1][4]. Company Overview - Organon & Co. develops health solutions through prescription therapies and medical devices [3]. Allegations of the Lawsuit - The lawsuit claims that Organon misrepresented the risks associated with its product Nexplanon, suggesting that the company would achieve $1 billion in sales by the end of fiscal year 2025, which is now deemed unlikely [4]. - It is alleged that Organon would not maintain the required $1 billion in free cash flow to sustain its dividend, nor would it maintain a debt leverage ratio of 4.0x, potentially affecting its corporate debt ratings [4]. - Following the announcement of its first quarter 2025 financial results, Organon reduced its dividend by 90%, which led to a stock price drop of over 27% [5]. Legal Process - Investors who purchased Organon securities during the Class Period can seek to be appointed as lead plaintiff in the class action lawsuit, representing the interests of all class members [7].